Abstract
A worldwide epidemic of type 2 diabetes has been in progress since the
mid-1980s, according to the World Health Organization. The worldwide number of
diabetics was 30 million in 1985 and is projected to increase to at least 366
million by 2030.
In the United States, an estimated 33% of people with type 2 diabetes have a
serious co-morbidity associated with the disease, and almost 8% of diabetics
have 4 or more of these complications, according to a report from the American
Association of Clinical Endocrinologists (AACE).
In Diabetes and Its Complications: Strategies to Advance Therapy and
Optimize R&D, a new report from Insight Pharma Reports (formerly Advances
Reports), author Allan B. Haberman, PhD, provides a strategic perspective on
the field of drugs for diabetes and its complications, with an emphasis on
novel and emerging drugs and therapeutic strategies.
In the United States, almost 21 million people, or 7% of the population, have
diabetes, and an estimated 54 million people are in a state of prediabetes,
according to the American Diabetes Association. The AACE report estimates the
direct medical costs related to diabetes complications in 2006 alone amounted
to $22.9 billion in the United States. Typical complications from diabetes
include heart attack, chronic kidney disease, congestive heart failure,
stroke, coronary heart disease, foot problems, and eye damage.
Diabetes and Its Complications: Strategies to Advance Therapy and Optimize
R&D gives individuals involved in the research, development, licensing,
and portfolio management of current and potential diabetes therapies a
complete picture of today' s therapeutic landscape, including:
- Background for understanding the nature, epidemiology, pathobiology, and
cost of diabetes
- Experimental therapeutic strategies for prevention of type 1 diabetes in
susceptible individuals.
- The pathogenesis of type 2 diabetes and its relationship to obesity
- Current diagnosis and treatment modalities for diabetes, types 1 and 2
- An evaluation of competitors in the diabetes market-their pipelines and
specific products, alliances, therapeutic focus, and more
- Assessment of novel classes of antidiabetics that include drugs introduced
into the market in 2005 and 2006, as well as drugs in still newer classes now
in corporate pipelines
- Assessment of leading research and preclinical-stage drugs, and novel
therapeutic strategies for type 2 diabetes
- Assessment of agents in development for diabetic complications, including
a novel unifying model for induction of microvascular complications, and a
novel model for induction of macrovascular complications
- The market outlook for new antidiabetic drugs
The report also includes a survey conducted by CHI in January 2007 of the
views and plans of individuals at the forefront of R&D for diabetes and its
complications.
The worldwide epidemic in diabetes, overwhelmingly type 2 diabetes, is driven
by increased rates of obesity, especially in industrialized countries and in
emerging industrial countries such as India and China, coupled with the aging
of the populations in both sets of countries. A key factor in the discovery
and development of successful new antidiabetic drugs is addressing the major
unmet needs in type 2 diabetes, especially the need for drugs that both lower
blood glucose and enable patients to lose weight, and the need to slow or
reverse the decline in pancreatic beta-cell function, which is the major cause
of the progression of the disease. Other unmet needs include:
- Treatments for diabetic complications
- Methods to prevent the development of type 1 diabetes in susceptible
individuals
- Better strategies to prevent type 2 diabetes in prediabetic individuals
Diabetes and Its Complications: Strategies to Advance Therapy and Optimize
R&D, with thorough analyses of the therapeutic sectors, combined with
detailed tables and figures, puts this complex disease and its sequelae in
perspective.
View Cart
